First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85 years.
Epistemonikos ID: 66a2518ba39946c080fc6850fa0ffa4200c04cd4
First added on: May 23, 2025